Developing-potential-treatment-for-severe-COVID

Boehringer Ingelheim Begins Phase 2 Clinical Trial of a Targeted Therapy to Help People with Severe Respiratory Illness from COVID-19Trial will evaluate BI 764198, a novel first-in-class compound, for hospitalized people infected with SARS-CoV-2 with severe respiratory complications for which very limited treatment options are currently available.This new therapeutic option could help the 67-85% of COVID-19 patients admitted to the intensive care unit who suffer from acute respiratory distress syndrome,1 potentially reducing the need for mechanical ventilation and potentially saving lives.The initiation of this Phase 2 trial is part of Boehringer Ingelheim ’s ongoing efforts to accelerate the discovery and development of urgently needed medicines for COVID-19 patients.
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news